TICKERNERD
Menu
ANABANABHealthcare · Biotechnology

ANAB Stock Forecast: AnaptysBio, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$46
+1.23% on the day

The 8 Wall Street analysts covering AnaptysBio, Inc. hold a median 12-month price target of $80 — +72.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.4B
Ticker Nerd rank
82 / 100
Median analyst target
$80
Analysts covering
8
Revenue$25.6M−8.0% y/y
Operating income−$34.6M
Net income−$52.9M
Free cash flow−$25.9M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.0%
1M
−18.4%
YTD
+43.0%
1Y
+117.8%
From 52W high
−33.8%
From 52W low
+121.0%
$21
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANAB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AnaptysBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
95
Volatility
93
Value
88
Issuance
80
Momentum
79
Quality
73
Size
40
Revisions
34
Accruals
26

Growth (95): Sales and profits are climbing, and climbing faster than before.

Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANAB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANAB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26ANABHigh $140Median $80Low $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $60Median $80High $140

The green dot is the last close — the median target sits +72.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
30 Sept 2026JP MorganMaintainsOverweight$70 → $60
24 Sept 2026HC Wainwright & Co.ReiteratesBuy$95
23 Sept 2026Leerink PartnersMaintainsOutperform$90 → $81
25 Aug 2026TD CowenMaintainsBuy$75 → $70
25 Aug 2026TD CowenMaintainsBuy—
24 Aug 2026HC Wainwright & Co.ReiteratesBuy$95
24 Aug 2026HC Wainwright & Co.ReiteratesBuy—
10 June 2026HC Wainwright & Co.AssumesBuy$95
13 May 2026BarclaysMaintainsOverweight—
13 May 2026UBSMaintainsBuy—
4 May 2026Piper SandlerMaintainsOverweight—
28 Apr 2026Leerink PartnersMaintainsOutperform—
22 Apr 2026BarclaysMaintainsOverweight—
21 Apr 2026UBSMaintainsBuy—
31 Mar 2026Piper SandlerMaintainsOverweight—
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
17 Mar 2026UBSMaintainsBuy—
12 Mar 2026WedbushMaintainsOutperform—
9 Mar 2026Truist SecuritiesMaintainsHold—
5 Mar 2026StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANAB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANAB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, AnaptysBio, Inc. returned +117.8% against +16.2% for the S&P 500, dividends included.

ANAB vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26ANABS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANAB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

AnaptysBio, Inc. (ANAB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−104.2×

Cheaper than 99% of US stocks

Price / sales
13.5×

Cheaper than 12% of US stocks

Price / book
134.5×

Cheaper than 1% of US stocks

EV / EBITDA
23.4×

Cheaper than 12% of US stocks

Growth & margins
Revenue growth (YoY)
23.5%

Higher than 73% of US stocks

Earnings growth (YoY)
−8.0%

Higher than 28% of US stocks

Gross margin
—
Operating margin
53.4%

Higher than 97% of US stocks

Net margin
247.0%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−35.6%

Higher than 26% of US stocks

Return on assets
−3.6%

Higher than 34% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AnaptysBio, Inc. (ANAB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AnaptysBio, Inc. has a market value of $1.4B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 31 Mar 2026: $232.4M. The latest quarter grew 23.5% year on year.

  • Net income over the same four quarters: −$26.8M, a −11.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.08.

  • Free cash flow in the twelve months to 31 Mar 2026: $4.4M, after $69K of capital spending.

  • AnaptysBio, Inc. spent $64.2M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 29.0M.

  • Trailing P/E: −104.2×; forward P/E: 9.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • AnaptysBio, Inc. employs 104 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ANAB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANABAnaptysBio, Inc.$1.4B
82
TYRATyra Biosciences, Inc.$1.4B
31
INBXInhibrx Biosciences, Inc.$1.4B
27
OMEROmeros Corp.$1.4B
93
NKTRNektar Therapeutics$1.4B
48
GHRSGH Research PLC$1.4B
62
KARDKardigan, Inc.$1.3B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AnaptysBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANAB news & analysis

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 21 Sept 2026positive

AnaptysBio reported a second-quarter loss of $0.11 per share, narrower than the Zacks Consensus Estimate loss of $0.46 and better than the $1.34 loss a year ago. The company also topped revenue estimates for the quarter.

Why it matters — The result shows AnaptysBio's quarterly loss was much smaller than analysts expected and improved sharply year over year, which ANB watchers would see as a positive sign for its financial performance.

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

GlobeNewsWire · 21 Sept 2026neutral

AnaptysBio reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update. The company manages financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda.

Why it matters — ANAB watchers will want to track the company's quarterly financial results and business update, as these reflect the status of its collaborations with Tesaro/GSK and Vanda.

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 1 Sept 2026neutral

AnaptysBio announced that chief financial officer Chris Murphy is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 15, 2026, at 3:30pm ET. The company noted its financial collaborations with GSK for Jemperli and with Vanda for imsidolimab.

Why it matters — An ANAB watcher would care because a CFO presentation at a major investment conference provides an opportunity for the company to communicate with investors about its financial collaborations.

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

Zacks Investment Research · 24 Aug 2026neutral

GSK's supplemental Biologics License Application for Jemperli has been granted FDA priority review for dMMR/MSI-H rectal cancer, with a decision expected in February 2027. Separately, GSK's Hibsago received approval in Japan for chronic hepatitis B.

Why it matters — This item concerns GSK's oncology and hepatitis B pipeline developments rather than AnaptysBio, so it provides no direct indication about ANAB's outlook but signals competitive activity in the broader biopharma space.

AnaptysBio: The Royalty Waterfall Is About To Reverse

Seeking Alpha · 29 July 2026positive

AnaptysBio has repositioned as a focused royalty management company, with its value primarily tied to Jemperli royalties from GSK. The company now operates virtually with a 95% targeted EBIT margin and over $140M net cash, having eliminated its prior R&D burn.

Why it matters — ANAB watchers would care because once the Sagard obligation is paid by mid-2027, the company will retain high-margin, growing royalty streams that escalate with Jemperli sales.

FAQ

Frequently asked questions about ANAB stock

What is the ANAB stock price forecast for 2026-2027?

The 8 Wall Street analysts covering AnaptysBio, Inc. have a median 12-month price target of $80, with estimates ranging from $60 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANAB stock a buy right now?

Of the 8 analysts covering AnaptysBio, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AnaptysBio, Inc. 82 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANAB?

As at 8 Oct 2026, AnaptysBio, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).

Will ANAB stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +72.0% from the last close, and Ticker Nerd's factor model ranks AnaptysBio, Inc. 82 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANAB stock forecast for 2030?

No analyst covering AnaptysBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $140 over the next 12 months.

How has ANAB stock performed over the past year?

AnaptysBio, Inc. returned +117.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AnaptysBio, Inc. do?

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases.

What is the latest news on ANAB?

The most recent item we track (Zacks Investment Research, 21 Sept 2026): "AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates". AnaptysBio reported a second-quarter loss of $0.11 per share, narrower than the Zacks Consensus Estimate loss of $0.46 and better than the $1.34 loss a year ago. The company also topped revenue estimates for the quarter.

Company

About AnaptysBio, Inc.

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets. Its portfolio includes investigational therapies aimed at conditions such as rheumatoid arthritis, ulcerative colitis, atopic dermatitis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. The company also manages financial collaborations tied to partnered assets, reflecting a business model that combines internal drug development with externally partnered programs. Based in San Diego, California, AnaptysBio plays a role in the biotechnology market as a specialist in immune cell modulation and antibody therapeutics.

CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.anaptysbio.com